The prognosis of patients diagnosed with advanced melanoma has dramatically improved since the introduction of anti-PD-1-based immunotherapy and targeted therapy with BRAF and MEK inhibitors for BRAF-mutated patients [2,3,4,5]. The gene discussed is BRAF; the disease is melanoma.